Health Canada approves AstraZeneca’s COVID-19 vaccine for use

Adding to the list of approved COVID-19 vaccines in the country, Health Canada has just given the green light to AstraZeneca’s vaccine for widespread use.

As of the official announcement Friday morning, AstraZeneca’s vaccine joins the Pfizer-BioNTech and Moderna vaccines as a safe and effective option for immunization against COVID-19 in Canada, with the federal government having already purchased 20 million doses.

The AstraZeneca viral vector vaccine – administered in two doses – is intended for use by individuals over the age of 18, with an estimated efficacy of 62.1 per cent; not quite as extraordinary as the efficacy of Pfizer and Moderna’s respective vaccines, but still a strong option in the fight against this pandemic.

Additionally, though Health Canada has said it has no immediate concerns about the safety of AstraZeneca’s vaccine, clinical trials results were too limited for a reliable gauge of the vaccine’s efficacy in those over the age of 65.

However, efficacy in those more senior age groups will be updated as additional data is gathered.

Currently, Health Canada is also reviewing two other promising vaccine candidates: the single-dose vaccine from Johnson & Johnson, and a candidate made by Novavax.

Read more about the AstraZeneca COVID-19 vaccine here.

Comments (0)